AI Case Study
Abbvie achieves 90% cumulative medication adherence among patients with schizophrenia using image recognition
Abbvie used AiCure’s artificial intelligence platform to visually confirm medication ingestion. This has facilitated continuous monitoring of patient treatment leading to better compliance and streamlining of clinical trials by reducing sample size.
Pharmaceuticals And Biotech
AiCure uses visual recognition to confirm medication ingestion using smartphones, and has managed to significantly increase medication adherence among patients. This was tested in patients with Schizophrenia, measured by drug concentration levels.
90% medication adherence compared to 72% before.
Technical And Product Support
Abbvie is a biopharmaceutical company founded in 2013.